Involving Igm Patents (Class 424/806)

Cross-Reference Art Collections

Monoclonal (Class 424/807)
  • Patent number: 8790650
    Abstract: The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: July 29, 2014
    Assignee: Vanderbilt University
    Inventors: Ethan Lee, Pampee P. Young, Josiane Eid
  • Patent number: 7514079
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: April 7, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Patent number: 7311912
    Abstract: Targeting molecules for use in delivering biological agents to epithelial tissue are disclosed. Upon delivery, the biological agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used, for example, for the delivery of therapeutic agents.
    Type: Grant
    Filed: January 9, 1998
    Date of Patent: December 25, 2007
    Assignee: Plantbodies Corporation
    Inventors: Mich B. Hein, Andrew C. Hiatt, John H. Fitchen
  • Patent number: 6828113
    Abstract: The present invention provides a method for detecting the presence of cytomegalovirus (CMV) in a fetal sample by determining the presence of anti-hsp70 antibodies present in the fetal sample. The invention further provides a method for monitoring CMV infection in a human fetus. In another embodiment, the invention provides a method for detecting CMV in a cord blood sample of a neonate.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: December 7, 2004
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Steven S. Witkin
  • Patent number: 6261536
    Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: July 17, 2001
    Assignee: RhoMed Incorporated
    Inventors: Paul O. Zamora, Michael J. Marek
  • Patent number: 6025141
    Abstract: The present invention relates to the use of insoluble forms of recombinant proteins in a flow cytometric immunofluorescence assay for the detection of given antibodies.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: February 15, 2000
    Assignee: The Canadian Red Cross Society
    Inventor: Yu-Wen Hu
  • Patent number: 5827534
    Abstract: An oral dosage composition for intestinal delivery of a therapeutic agent comprising:(A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and(B) an intestinal absorption enhancing effective amount of purified Vibrio cholera zonula occludens toxin.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: October 27, 1998
    Assignee: University of Maryland at Baltimore
    Inventor: Alessio Fasano
  • Patent number: 5543143
    Abstract: There is disclosed a method of treating a mammal infected with a macrophage pathogen comprising administering an effective amount of a TGF-.beta. antagonist. Macrophage pathogens include any pathogenic microorganism that replicates within macrophage cell hosts as their exclusive or primary host cells. TGF-.beta. antagonists include blocking antibodies specific for a human TGF-.beta., soluble TGF-.beta. receptors, protease inhibitors that inactivate a protease responsible for activating a precursor TGF-.beta. into an active, mature TGF-.beta., and combinations thereof.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: August 6, 1996
    Assignee: Corixa Corporation
    Inventor: Steven G. Reed